<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00349466</url>
  </required_header>
  <id_info>
    <org_study_id>CF101-201KCS</org_study_id>
    <nct_id>NCT00349466</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca</brief_title>
  <official_title>A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Keratoconjunctivitis Sicca</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Can-Fite BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Can-Fite BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, double-masked, placebo-controlled, parallel-group study in
      adult males and females, aged 18 years and over, with a diagnosis of moderate-to-severe
      keratoconjunctivitis sicca (KCS). Patients will be randomized to receive either CF101 1 mg or
      matching placebo, given orally every 12 hours (q12h) for 12 weeks. A Screening Period of up
      to 4 weeks that includes a 2-week run-in period will precede a 12-week treatment period,
      followed by a 2-week follow-up period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At a Screening Visit, patients who provide written informed consent will have screening
      procedures performed, including a complete medical history, medication history, physical
      examination, including height, weight, sitting blood pressure, pulse rate and temperature,
      and clinical laboratory tests. Disease activity will be assessed using tear meniscus (TM)
      height, tear break-up time (BUT), fluorescein staining (FS), Schirmer test, and the Dry Eye
      Symptom Score (DESS). Doses of artificial tears must be stable for &gt;2 weeks prior to the
      Screening Visit.

      Eligible patients will begin a 2-week run-in period, during which time they will be
      instructed to discontinue use of all topical ophthalmic medications except for lubricant eye
      drops. Patients who successfully complete the 2-week run-in period will be randomized to
      their assigned medication (CF101 1 mg or matching placebo) to be taken orally every q12h for
      12 weeks. Patients will return for assessments and a new supply of study medication at Weeks
      2, 4, 8 and 12, and at Week 14 for a final follow-up assessment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Schirmer Test (ST)</measure>
    <time_frame>12 weeks</time_frame>
    <description>involved placing a standardized paper tear strip inside the lower eyelid for 5 minutes. The tear strip was then removed and the length of the strip that was wet from tears was measured in millimeters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tear Break-Up Time</measure>
    <time_frame>12 weeks</time_frame>
    <description>time elapsed between a complete blink and the development of the first random dry spot on the tear film</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fluorescein Staining of the Cornea</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Severity of corneal epithelial loss as graded by Fluorescein Staining of the cornea, assessed on a 0-4+ scale with 0 = none and 4+ = severe de-epithelialization, expressed as number of participants with &gt;25% improvement at Week 12 relative to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Clinical Success</measure>
    <time_frame>12 weeks</time_frame>
    <description>improvement of ≥25% over baseline at Week 12 in BUT, superficial punctate keratitis as assessed by FS, or ST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dry Eye Symptom Score</measure>
    <time_frame>12 weeks</time_frame>
    <description>consists of 12 questions designed to assess the symptoms of ocular irritations, covering three areas: ocular symptoms, environmental triggers and visionrelated function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Meniscus (TM) Height</measure>
    <time_frame>12 weeks</time_frame>
    <description>Indicator of tear volume. TM was recorded on a scale from 0-3, with 0=none, 1=trace, 2=normal, and 3=high.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Artificial Tears</measure>
    <time_frame>12 weeks</time_frame>
    <description>daily use of REFRESH TEARS® Lubricant Eye Drops artificial tears supplied to each patient was recorded in diaries provided to patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Keratoconjunctivitis Sicca</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CF101 1 mg given orally every 12 hours for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given orally every 12 hours for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CF101</intervention_name>
    <description>Orally CF101 1mg</description>
    <arm_group_label>1</arm_group_label>
    <other_name>IB-MECA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Orally matching Placebo</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Inactive pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 years of age and over;

          -  Have a diagnosis of moderate-to-severe KCS as defined by: (1) ST (without anesthesia)
             &lt; 7 mm/5 min in either eye; AND (2) Positive FS, defined as a corneal punctate
             fluorescein staining score of ≥1 in either eye, where 0 = none and 3= severe; AND (3)
             At least 1 of the following ocular symptoms scored at ≥2, where 0 = none and 4 = very
             severe/interferes with normal activities: photophobia, blurred vision, foreign body
             sensation, soreness or pain, itching, burning, dryness;

          -  Willing to use no topical ocular treatments except for the unpreserved artificial
             tears;

          -  Doses of unpreserved artificial tears have been stable for &gt;2 weeks prior to Screening
             Visit;

          -  Females of child-bearing potential must have a negative urine pregnancy test at
             screening and throughout the study, to be eligible for, and continue participation in,
             the study;

          -  Females of child-bearing potential must be willing to use 2 methods of contraception
             deemed adequate by the Investigator (for example oral contraceptive pills plus a
             barrier method) to be eligible for, and continue participation in, the study;

          -  Ability to complete the study in compliance with the protocol; and

          -  Ability to understand and provide written informed consent.

        Exclusion Criteria:

          -  Has Sjögren's Syndrome with significant systemic non-exocrine gland involvement;

          -  Has Stevens-Johnson Syndrome;

          -  If KCS is due to rheumatoid arthritis or other autoimmune diseases, patient may not be
             receiving disease-modifying drugs, including methotrexate and biological agents;

          -  Use of systemic immunosuppressive drugs;

          -  Use of oral corticosteroids &gt;10 mg prednisone, or equivalent, per day;

          -  Use of topical steroids within 2 weeks prior to the Screening Visit and for the
             duration of the study;

          -  Receipt of topical cyclosporine eye drops within 3 months prior to the Screening Visit
             and for the duration of the trial;

          -  Presence of chronic ocular disease other than KCS requiring topical treatment;

          -  Presence of post-burn ocular injury;

          -  Ocular herpes simplex virus infection;

          -  Concomitant use of contact lenses;

          -  Persistent intraocular inflammation or infection;

          -  Active blepharitis;

          -  Recent surgical occlusion of the lacrimal puncta;

          -  Subepithelial corneal scarring;

          -  Anesthetic or neurotrophic corneas;

          -  Hemoglobin level &lt;9.0 gm/L;

          -  Platelet count &lt;125,000/mm^3;

          -  White blood cell count &lt;3500/mm^3;

          -  Serum creatinine level outside the laboratory's normal limits;

          -  Liver aminotransferase levels greater than 2 times the laboratory's upper limit of
             normal;

          -  Pregnancy, planned pregnancy, lactation, or inadequate contraception as judged by the
             Investigator;

          -  History of malignancy within the past 5 years (excluding basal cell carcinoma of the
             skin);

          -  Significant acute or chronic medical, ophthalmic, or psychiatric illness that, in the
             judgment of the Investigator, could compromise patient safety, limit the patient's
             ability to complete the study, and/or compromise the objectives of the study;

          -  Participation in another investigational drug or vaccine trial concurrently or within
             30 days; or

          -  Other conditions which would confound the study evaluations or endanger the safety of
             the patient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irit Bareket, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Meir Hospital</name>
      <address>
        <city>Kfar-Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>5262</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center</name>
      <address>
        <city>Zeriffin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.canfite.com/</url>
    <description>Can-Fite BioPharma web site</description>
  </link>
  <results_reference>
    <citation>Avni I, Garzozi HJ, Barequet IS, Segev F, Varssano D, Sartani G, Chetrit N, Bakshi E, Zadok D, Tomkins O, Litvin G, Jacobson KA, Fishman S, Harpaz Z, Farbstein M, Yehuda SB, Silverman MH, Kerns WD, Bristol DR, Cohn I, Fishman P. Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial. Ophthalmology. 2010 Jul;117(7):1287-93. doi: 10.1016/j.ophtha.2009.11.029. Epub 2010 Mar 20.</citation>
    <PMID>20304499</PMID>
  </results_reference>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2006</study_first_submitted>
  <study_first_submitted_qc>July 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2006</study_first_posted>
  <results_first_submitted>June 20, 2011</results_first_submitted>
  <results_first_submitted_qc>July 19, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 12, 2011</results_first_posted>
  <last_update_submitted>February 12, 2015</last_update_submitted>
  <last_update_submitted_qc>February 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Keratoconjunctivitis Sicca</keyword>
  <keyword>KCS</keyword>
  <keyword>Dry Eye</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CF101 1 mg</title>
          <description>CF101 1 mg q12 hours</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo tablets q12 hours for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CF101 1 mg</title>
          <description>CF101 1 mg q12 hours</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo tablets q12 hours for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.2" spread="14.4"/>
                    <measurement group_id="B2" value="61.4" spread="1311.7"/>
                    <measurement group_id="B3" value="58.7" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Schirmer Test (ST)</title>
        <description>involved placing a standardized paper tear strip inside the lower eyelid for 5 minutes. The tear strip was then removed and the length of the strip that was wet from tears was measured in millimeters</description>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tear Break-Up Time</title>
        <description>time elapsed between a complete blink and the development of the first random dry spot on the tear film</description>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fluorescein Staining of the Cornea</title>
        <description>Severity of corneal epithelial loss as graded by Fluorescein Staining of the cornea, assessed on a 0-4+ scale with 0 = none and 4+ = severe de-epithelialization, expressed as number of participants with &gt;25% improvement at Week 12 relative to baseline</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Per protocol, observed values</population>
        <group_list>
          <group group_id="O1">
            <title>CF101 1 mg BID</title>
            <description>Oral tablets given every 12 hours for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo BID</title>
            <description>Oral tablets given every 12 hours for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Fluorescein Staining of the Cornea</title>
          <description>Severity of corneal epithelial loss as graded by Fluorescein Staining of the cornea, assessed on a 0-4+ scale with 0 = none and 4+ = severe de-epithelialization, expressed as number of participants with &gt;25% improvement at Week 12 relative to baseline</description>
          <population>Per protocol, observed values</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Clinical Success</title>
        <description>improvement of ≥25% over baseline at Week 12 in BUT, superficial punctate keratitis as assessed by FS, or ST</description>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dry Eye Symptom Score</title>
        <description>consists of 12 questions designed to assess the symptoms of ocular irritations, covering three areas: ocular symptoms, environmental triggers and visionrelated function</description>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tear Meniscus (TM) Height</title>
        <description>Indicator of tear volume. TM was recorded on a scale from 0-3, with 0=none, 1=trace, 2=normal, and 3=high.</description>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Artificial Tears</title>
        <description>daily use of REFRESH TEARS® Lubricant Eye Drops artificial tears supplied to each patient was recorded in diaries provided to patients</description>
        <time_frame>12 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Starting on week 2 till week 12 and continue till foloow up visit on week 14</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CF101 1 mg</title>
          <description>CF101 1 mg q12 hours</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo tablets q12 hours for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pnina Fishman, PhD</name_or_title>
      <organization>Can-Fite Biopharma</organization>
      <phone>011972 3 924 1114</phone>
      <email>pnina@canfite.co.il</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

